HomepageAXGN • NASDAQ
add
AxoGen, Inc Common Stock
Vorige slotkoers
$ 18,05
Dag-range
$ 17,17 - $ 18,49
Jaar-range
$ 5,56 - $ 18,49
Beurswaarde
791,71 mln. USD
Gem. volume
391,56K
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | sep 2024info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 48,64 mln. | 17,86% |
Bedrijfskosten | 36,75 mln. | 2,87% |
Netto inkomsten | -1,86 mln. | 54,56% |
Netto winstmarge | -3,82 | 61,45% |
Winst per aandeel | 0,07 | 600,00% |
EBITDA | 1,40 mln. | 150,05% |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
| (USD) | sep 2024info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 24,53 mln. | -24,73% |
Totale activa | 191,98 mln. | -1,36% |
Totale passiva | 92,58 mln. | -4,38% |
Totaal aandelenvermogen | 99,41 mln. | — |
Uitstaande aandelen | 44,01 mln. | — |
Koers-boekwaardeverhouding | 7,99 | — |
Rendement op activa | -0,41% | — |
Rendement op kapitaal | -0,47% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | sep 2024info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -1,86 mln. | 54,56% |
Operationele kasstroom | 3,90 mln. | 139,91% |
Kasstroom uit beleggingen | -5,00 mln. | -183,42% |
Kasstroom uit financiering | 572,00K | 11.340,00% |
Nettomutatie in liquide middelen | -527,00K | -106,91% |
Vrije kasstroom | 3,60 mln. | 424,35% |
Over
Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available allograft approved by the Food and Drug Administration for clinical use. Wikipedia
Opgericht
2002
Hoofdvestiging
Website
Werknemers
427
